Research graph
References from A novel cereblon variant with both exon 8 and 10 deletions in newly diagnosed and relapsed multiple myeloma. Local targets link to admitted publications; unresolved targets remain external evidence.
Identification of a primary target of thalidomide teratogenicity
10.1126/science.1177319 · 2010 · External reference
Cereblon expression is required for the antimyeloma activity of lenalidomide and pomalidomide
10.1182/blood-2011-05-356063 · 2011 · External reference
Molecular glue CELMoD compounds are regulators of cereblon conformation
10.1126/science.add7574 · 2022 · External reference
IMiD resistance in multiple myeloma: current understanding of the underpinning biology and clinical impact
2023 · External reference
Transcriptional heterogeneity overcomes super-enhancer disrupting drug combinations in multiple myeloma
10.1158/2643-3230.bcd-23-0062 · 2024 · External reference
ETV4-dependent transcriptional plasticity maintains MYC expression and results in IMiD resistance in multiple myeloma
10.1158/2643-3230.bcd-23-0061 · 2024 · External reference
Identification of lenalidomide resistance pathways in myeloma and targeted resensitization using cereblon replacement, inhibition of STAT3 or targeting of IRF4
10.1038/s41408-019-0173-0 · 2019 · External reference
Transcriptional profiles define drug refractory disease in myeloma
10.1002/jha2.455 · 2022 · External reference
Multiple cereblon genetic changes are associated with acquired resistance to lenalidomide or pomalidomide in multiple myeloma
10.1182/blood.2020007081 · 2021 · External reference
Cereblon splicing of exon 10 mediates IMiDs resistance in multiple myeloma: clinical validation in the CoMMpass trial
10.1182/blood.v128.22.120.120 · 2016 · External reference
A simple and reliable method to verify the authenticity and purity of human myeloma cell lines
10.1182/blood.v110.11.2485.2485 · 2007 · External reference
Comparative studies of AlphaFold, RoseTTAFold and Modeller: a case study involving the use of G-protein-coupled receptors
10.1093/bib/bbac308 · 2022 · External reference
Replica-exchange molecular dynamics method for protein folding
10.1016/s0009-2614(99)01123-9 · 1999 · External reference
Determining protein structures by combining semireliable data with atomistic physical models by Bayesian inference
10.1073/pnas.1506788112 · 2015 · External reference
CryoFold: determining protein structures and data-guided ensembles from cryo-EM density maps
10.1016/j.matt.2021.09.004 · 2021 · External reference
CHARMM-GUI ligand reader and modeler for CHARMM force field generation of small molecules
10.1002/jcc.24829 · 2017 · External reference
CHARMM36m: an improved force field for folded and intrinsically disordered proteins
10.1038/nmeth.4067 · 2017 · External reference
Structure and dynamics of the TIP3P, SPC, and SPC/E water models at 298 K
10.1021/jp003020w · 2001 · External reference
Scalable molecular dynamics with NAMD
10.1002/jcc.20289 · 2005 · External reference
Scalable molecular dynamics on CPU and GPU architectures with NAMD
10.1063/5.0014475 · 2020 · External reference
VMD: visual molecular dynamics
10.1016/0263-7855(96)00018-5 · 1996 · External reference
Unresolved reference
2016 · External reference
MDTraj: a modern open library for the analysis of molecular dynamics trajectories
10.1016/j.bpj.2015.08.015 · 2015 · External reference
Identification of cereblon-binding proteins and relationship with response and survival after IMiDs in multiple myeloma
10.1182/blood-2014-02-557819 · 2014 · External reference
Incorporation of digital gene expression profiling for cell-of-origin determination (Lymph2Cx Testing) into the routine work-up of diffuse large B-cell lymphoma
10.1007/s12308-019-00344-0 · 2019 · External reference
The application and biology of immunomodulatory drugs (IMiDs) in cancer
10.1016/j.pharmthera.2012.07.004 · 2012 · External reference
Avadomide monotherapy in relapsed/refractory DLBCL: safety, efficacy, and a predictive gene classifier
10.1182/blood.2019002395 · 2020 · External reference
Immunomodulatory drugs for the treatment of B cell malignancies
10.3390/ijms22168572 · 2021 · External reference
